Lung Cancer Trials Ask AI to find trials
RecruitingNot applicableNCT07028489
Official study title

Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer

Study summary

The objective of this study is to build a prospective cohort in patients with locally advanced or metastatic NSCLC with common EGFR mutations. In NPM-002, there will be standardized data collection at baseline, on-treatment and at discontinuation of therapy. Patients who enroll prior to initiation of osimertinib treatment (\~30%) will undergo imaging with standardized intervals.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedNot specified

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · EGFR · Locally advanced

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 22, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Not applicable

Observational

Where is it offered?10 U.S. locations

Locations may change over time.

Who runs it?N-Power Medicine

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
N-Power Medicine
Interventions being studied
Not specified
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Disease setting
Locally advanced→Metastatic or stage IV→
Biomarkers
EGFR→
Treatment approach
Targeted therapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Be ≥18 years of age at the time of informed consent
  • Evidence of a confirmed diagnosis of EGFR mutant (EGFR exon 19del or EGFR exon 21 L858R) locally advanced or metastatic NSCLC diagnosed on Jan 1st 2024 or later.
Reasons someone may not be able to joinExclusion criteria
  • ECOG≥2 at diagnosis of advanced or metastatic NSCLC
  • Evidence of prior treatment with osimertinib, amivantamab or lazertinib. For the planned selection and analysis of external controls, further eligibility criteria will be applied according to the COPERNICUS SAP.

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Pacific Cancer CareMonterey, California
  • Torrance Memorial Physician Network-Cancer CareTorrance, California
  • John Muir HealthWalnut Creek, California
  • Bayhealth Cancer Center- KentDover, Delaware
  • Bayhealth Cancer Center- SussexMilford, Delaware
  • Kootenai Clinic Cancer Services Coeur d'AleneCoeur d'Alene, Idaho
  • Northwest Oncology & HematologyElk Grove Village, Illinois
  • New Mexico Oncology Hematology ConsultantsAlbuquerque, New Mexico
  • Lankenau Medical CenterPaoli, Pennsylvania
  • Oncology Consultants, P.A.Houston, Texas

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 22, 2026. Always confirm current availability with the study team.

View original record ↗